Neurocrine Biosciences reported $835.47 in PE Price to Earnings for its fiscal quarter ending in December of 2025.





Pe Change Date
AbbVie USD 24.03 86.23 Dec/2025
Acadia Pharmaceuticals USD 13.7 2.49 Sep/2025
Agios Pharmaceuticals USD 3.56 0.68 Sep/2025
ALKERMES USD 19.54 4.64 Dec/2025
Alnylam Pharmaceuticals 170.7 367.33 Dec/2025
Amgen USD 25.31 15.82 Dec/2025
Biogen USD 14.02 4.63 Dec/2025
BioMarin Pharmaceutical USD 19.24 0.21 Dec/2025
Exelixis USD 602.31 586.25 Dec/2025
Gilead Sciences USD 15.63 0.08 Dec/2025
Halozyme Therapeutics USD 23.16 7.7 Dec/2025
Incyte USD 14.84 2.79 Dec/2025
Ionis Pharmaceuticals USD 396.15 79.28 Sep/2022
Neurocrine Biosciences USD 835.47 802.2 Dec/2025
Pfizer USD 14.48 5.18 Dec/2025
Prothena USD 22.11 11.37 Mar/2022
Regeneron Pharmaceuticals USD 18.11 2.91 Dec/2025
Repligen USD 164.06 23.88 Dec/2025
Rigel Pharmaceuticals 8.61 8.4 Mar/2025
Sarepta Therapeutics USD 27.27 0 Sep/2025
Teva Pharmaceutical Industries USD 10.11 1.04 Dec/2025
Vertex Pharmaceuticals USD 26.15 2.22 Dec/2025
Xoma 52.12 3.09 Sep/2022